Marker Therapeutics Inc (Nasdaq:MRKR), a clinical-stage immuno-oncology company specialising in the development of next-generation T cell-based immunotherapies for the treatment of haematological malignancies and solid tumour indications, announced yesterday that it has named Nadia Agopyan, PhD, RAC as its new vice president of Regulatory Affairs, effective 15 August.
Dr Agopyan joins Marker from Kite Pharma where she served as director of Regulatory Affairs, global regulatory lead. Previously, she served as global regulatory lead at Baxter Biosciences, leading Vonvendi (recombinant von Willebrand Factor) approval/launch, senior director Regulatory Affairs at Ambit Biosciences, and director Regulatory Affairs at Cougar Biotechnology, a unit of Johnson and Johnson Ortho Biotech Oncology, where she led the approval of Zytiga, abiraterone acetate, for the treatment of patients with metastatic castrate-resistant prostate cancer. Earlier in her career, Dr Agopyan served in various roles at biotechnology companies such as Amgen, CATO Research and Allelix Biopharmaceuticals and as assistant professor in academia including Duke University and University of Toronto.
Peter L Hoang, president & CEO of Marker, said, 'We are pleased to welcome a professional of Nadia's calibre and senior leadership experience to Marker. With more than 15 years of industry knowledge in regulatory affairs and clinical development, Nadia will be instrumental in helping shape our regulatory strategy as we prepare to initiate the first Marker-sponsored trial with MultiTAA therapy in patients with post-transplant acute myeloid leukemia.'
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval